Last reviewed · How we verify

Servier (Tianjin) Pharmaceutical Co. LTD. — Portfolio Competitive Intelligence Brief

Servier (Tianjin) Pharmaceutical Co. LTD. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Biosynthetic Human Insulin Injection Biosynthetic Human Insulin Injection marketed
Gliclazide MR and Insulin Glargine Injection Gliclazide MR and Insulin Glargine Injection marketed

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Servier (Tianjin) Pharmaceutical Co. LTD.:

Cite this brief

Drug Landscape (2026). Servier (Tianjin) Pharmaceutical Co. LTD. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/servier-tianjin-pharmaceutical-co-ltd. Accessed 2026-05-16.

Related